D
Dongsheng Tu
Researcher at Queen's University
Publications - 307
Citations - 34887
Dongsheng Tu is an academic researcher from Queen's University. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 67, co-authored 271 publications receiving 32487 citations. Previous affiliations of Dongsheng Tu include Cancer Research Institute & Harvard University.
Papers
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Christos S. Karapetis,Shirin Khambata-Ford,Derek J. Jonker,Christopher J. O'Callaghan,Dongsheng Tu,Niall C. Tebbutt,R. John Simes,Haji Chalchal,Jeremy Shapiro,Sonia Robitaille,Timothy J. Price,Lois E. Shepherd,Heather-Jane Au,Christiane Langer,Malcolm J. Moore,John Zalcberg +15 more
TL;DR: Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ra did benefit fromcetuxIMab.
Journal ArticleDOI
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Christine Ribic,Daniel J. Sargent,Malcolm J. Moore,Malcolm J. Moore,Stephen N. Thibodeau,Amy J. French,Richard M. Goldberg,Stanley R. Hamilton,Stanley R. Hamilton,Pierre Laurent-Puig,Robert Gryfe,Lois E. Shepherd,Dongsheng Tu,Mark Redston,Steven Gallinger,Steven Gallinger +15 more
TL;DR: F fluorouracil-based adjuvant chemotherapy benefited patients with stage II or stage III colon cancer with microsatellite-stable tumors or tumors exhibiting low-frequency micros satellite instability but not those with tumors exhibiting high-frequencymicrosatellite instability.
Journal ArticleDOI
Cetuximab for the Treatment of Colorectal Cancer
Derek J. Jonker,Christopher J. O'Callaghan,Christos S. Karapetis,John Zalcberg,Dongsheng Tu,Heather-Jane Au,Scott R. Berry,Marianne Krahn,Timothy J. Price,R. John Simes,Niall C. Tebbutt,Guy van Hazel,Rafal Wierzbicki,Christiane Langer,Malcolm J. Moore +14 more
TL;DR: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed.
Book
The jackknife and bootstrap
Jun Shao,Dongsheng Tu +1 more
TL;DR: In this article, the authors proposed a method for estimating the variance of functions of means using the one-step jackknife, and showed that the method can be used to estimate the variance in the context of complex problems.